{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:07:28Z","timestamp":1778684848887,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson & Johnson, Singapore"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00929-9","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:14:11Z","timestamp":1775895251000},"page":"1387-1407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient- and Caregiver-Reported Burden and Quality of Life in Generalised Myasthenia Gravis: A Multinational Real-World Survey in the Asia\u2013Pacific Region"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1091-5792","authenticated-orcid":false,"given":"DaeYoung","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Kasahara-Kiritani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Ching","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva Lauretta","family":"Birija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Conyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"1","key":"929_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"key":"929_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10112235.","journal-title":"J Clin Med"},{"issue":"1","key":"929_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516. https:\/\/doi.org\/10.1186\/s12967-021-03185-7.","journal-title":"J Transl Med"},{"issue":"3","key":"929_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40120-024-00619-4","volume":"13","author":"NW Tsai","year":"2024","unstructured":"Tsai NW, Chien LN, Hung C, et al. Epidemiology, patient characteristics, and treatment patterns of myasthenia gravis in Taiwan: a population-based study. Neurol Ther. 2024;13(3):809\u201324. https:\/\/doi.org\/10.1007\/s40120-024-00619-4.","journal-title":"Neurol Ther"},{"key":"929_CR5","doi-asserted-by":"publisher","first-page":"1203679","DOI":"10.3389\/fneur.2023.1203679","volume":"14","author":"KJ Herr","year":"2023","unstructured":"Herr KJ, Shen SP, Liu Y, Yang CC, Tang CH. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. Front Neurol. 2023;14:1203679. https:\/\/doi.org\/10.3389\/fneur.2023.1203679.","journal-title":"Front Neurol"},{"issue":"9","key":"929_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274161","volume":"17","author":"H Yoshikawa","year":"2022","unstructured":"Yoshikawa H, Adachi Y, Nakamura Y, et al. Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS ONE. 2022;17(9):e0274161. https:\/\/doi.org\/10.1371\/journal.pone.0274161.","journal-title":"PLoS ONE"},{"issue":"1","key":"929_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13(1):e066445. https:\/\/doi.org\/10.1136\/bmjopen-2022-066445.","journal-title":"BMJ Open"},{"key":"929_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G, et al. The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci. 2022;437:120268. https:\/\/doi.org\/10.1016\/j.jns.2022.120268.","journal-title":"J Neurol Sci"},{"issue":"1","key":"929_CR9","doi-asserted-by":"publisher","first-page":"19275","DOI":"10.1038\/s41598-022-22078-3","volume":"12","author":"D Marbin","year":"2022","unstructured":"Marbin D, Piper SK, Lehnerer S, Harms U, Meisel A. Mental health in myasthenia gravis patients and its impact on caregiver burden. Sci Rep. 2022;12(1):19275. https:\/\/doi.org\/10.1038\/s41598-022-22078-3.","journal-title":"Sci Rep"},{"key":"929_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jocn.2023.11.024","volume":"119","author":"DD Meng","year":"2024","unstructured":"Meng DD, Ruan Z, Tang YL, et al. Factors associated with the disease family burden of caregivers of myasthenia gravis patients in northwestern China: a cross-sectional study. J Clin Neurosci. 2024;119:70\u20135. https:\/\/doi.org\/10.1016\/j.jocn.2023.11.024.","journal-title":"J Clin Neurosci"},{"issue":"10","key":"929_CR11","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s12325-023-02604-z","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Phillips G, Paci S, De Ruyck F, Tollenaar NH, Janssen MF. People diagnosed with myasthenia gravis have lower health-related quality of life and need more medical and caregiver help in comparison to the general population: analysis of two observational studies. Adv Ther. 2023;40(10):4377\u201394. https:\/\/doi.org\/10.1007\/s12325-023-02604-z.","journal-title":"Adv Ther"},{"issue":"6","key":"929_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacca","year":"2024","unstructured":"Sacca F, Salort-Campana E, Jacob S, Cortes-Vicente E, Schneider-Gold C. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024;31(6):e16180. https:\/\/doi.org\/10.1111\/ene.16180.","journal-title":"Eur J Neurol"},{"issue":"6","key":"929_CR13","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s40120-023-00544-y","volume":"12","author":"CA Hartford","year":"2023","unstructured":"Hartford CA, Sherman SA, Karantzoulis S, et al. Experience of daily life with generalized myasthenia gravis: a qualitative investigation and assessment of instrument content validity. Neurol Ther. 2023;12(6):2079\u201399. https:\/\/doi.org\/10.1007\/s40120-023-00544-y.","journal-title":"Neurol Ther"},{"issue":"4","key":"929_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","volume":"54","author":"E Guastafierro","year":"2020","unstructured":"Guastafierro E, Tramacere I, Toppo C, et al. Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology. 2020;54(4):304\u201312. https:\/\/doi.org\/10.1159\/000506310.","journal-title":"Neuroepidemiology"},{"issue":"4","key":"929_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mus.28063","volume":"69","author":"J Pesa","year":"2024","unstructured":"Pesa J, Choudhry Z, de Courcy J, et al. The impact of myasthenia gravis severity on work and daily activities. Muscle Nerve. 2024;69(4):428\u201339. https:\/\/doi.org\/10.1002\/mus.28063.","journal-title":"Muscle Nerve"},{"issue":"4","key":"929_CR16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40120-024-00617-6","volume":"13","author":"N Kawaguchi","year":"2024","unstructured":"Kawaguchi N, Tsuda K, Tanaka N, Kerstens R, Harada D. Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients\u2019 perspectives in Japan. Neurol Ther. 2024;13(4):1099\u2013113. https:\/\/doi.org\/10.1007\/s40120-024-00617-6.","journal-title":"Neurol Ther"},{"key":"929_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jocn.2023.09.023","volume":"118","author":"J Sansoni","year":"2023","unstructured":"Sansoni J, Menon N, Viali L, White S, Vucic S. Clinical features, treatments, their impact, and quality of life for myasthenia gravis patients in Australia. J Clin Neurosci. 2023;118:16\u201322. https:\/\/doi.org\/10.1016\/j.jocn.2023.09.023.","journal-title":"J Clin Neurosci"},{"key":"929_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1072861","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Li RY, Ye XB, Wang N. Reduced quality of life in myasthenia gravis patients: a study on 185 patients from China. Front Neurol. 2022;13:1072861. https:\/\/doi.org\/10.3389\/fneur.2022.1072861.","journal-title":"Front Neurol"},{"issue":"1","key":"929_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2451","volume":"12","author":"L Xu","year":"2022","unstructured":"Xu L, Wang X, Cui Y, et al. Illness perception characteristics and influencing factors in adult patients with myasthenia gravis in China. Brain Behav. 2022;12(1):e2451. https:\/\/doi.org\/10.1002\/brb3.2451.","journal-title":"Brain Behav"},{"issue":"11","key":"929_CR20","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372. https:\/\/doi.org\/10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"929_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. https:\/\/doi.org\/10.1136\/bmjopen-2015-010352.","journal-title":"BMJ Open"},{"key":"929_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380. https:\/\/doi.org\/10.2147\/DMSO.S120101.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"929_CR23","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"key":"929_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1673297","volume":"16","author":"M Kasahara-Kiritani","year":"2025","unstructured":"Kasahara-Kiritani M, Saga Y, Watanabe S, et al. Humanistic burden and medical care patterns of real-world patients with myasthenia gravis in Japan. Front Neurol. 2025;16:1673297. https:\/\/doi.org\/10.3389\/fneur.2025.1673297.","journal-title":"Front Neurol"},{"issue":"1","key":"929_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03869-9","volume":"24","author":"J Pesa","year":"2024","unstructured":"Pesa J, Choudhry Z, de Courcy J, et al. Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries. BMC Neurol. 2024;24(1):385. https:\/\/doi.org\/10.1186\/s12883-024-03869-9.","journal-title":"BMC Neurol"},{"issue":"1","key":"929_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02727-0","volume":"18","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, DeCourcy J, et al. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey. Orphanet J Rare Dis. 2023;18(1):169. https:\/\/doi.org\/10.1186\/s13023-023-02727-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"929_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16.","journal-title":"Neurology"},{"issue":"5","key":"929_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM, COMPOSITE atM, GROUP M-QS. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727\u201331. https:\/\/doi.org\/10.1002\/mus.22140.","journal-title":"Muscle Nerve"},{"issue":"7","key":"929_CR29","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139. https:\/\/doi.org\/10.1212\/wnl.52.7.1487.","journal-title":"Neurology"},{"issue":"18","key":"929_CR30","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434\u201340. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e.","journal-title":"Neurology"},{"issue":"6","key":"929_CR31","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38(6):1553\u201362. https:\/\/doi.org\/10.1002\/mus.21185.","journal-title":"Muscle Nerve"},{"issue":"7","key":"929_CR32","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"MF Janssen","year":"2013","unstructured":"Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717\u201327. https:\/\/doi.org\/10.1007\/s11136-012-0322-4.","journal-title":"Qual Life Res"},{"issue":"10","key":"929_CR33","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"4","key":"929_CR34","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662\u20139. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016.","journal-title":"Value Health"},{"issue":"5","key":"929_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"issue":"2","key":"929_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mus.21609","volume":"41","author":"TM Burns","year":"2010","unstructured":"Burns TM, Grouse CK, Conaway MR, Sanders DB. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010;41(2):219\u201326. https:\/\/doi.org\/10.1002\/mus.21609.","journal-title":"Muscle Nerve"},{"issue":"2","key":"929_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957\u201363. https:\/\/doi.org\/10.1002\/mus.21053.","journal-title":"Muscle Nerve"},{"key":"929_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79. https:\/\/doi.org\/10.1186\/1477-7525-1-79.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"929_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63\u201374. https:\/\/doi.org\/10.1016\/s0885-3924(96)00274-6.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"929_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"929_CR41","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/geront\/41.5.652","volume":"41","author":"M B\u00e9dard","year":"2001","unstructured":"B\u00e9dard M, Molloy DW, Squire L, Dubois S, Lever JA, O\u2019Donnell M. The Zarit Burden Interview: a new short version and screening version. Gerontologist. 2001;41(5):652\u20137. https:\/\/doi.org\/10.1093\/geront\/41.5.652.","journal-title":"Gerontologist"},{"key":"929_CR42","unstructured":"European Pharmaceutical Market Research Association (EPhMRA): Code of Conduct; 2022. https:\/\/www.ephmra.org\/sites\/default\/files\/2022-08\/EPHMRA%202022%20Code%20of%20Conduct.pdf. Accessed 25 Nov 2022."},{"key":"929_CR43","unstructured":"US Department of Health and Human Services: Summary of the HIPAA Privacy Rule; 2003. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed 17 Aug 2022."},{"key":"929_CR44","unstructured":"Health Information Technology (HITECH): Health Information Technology Act; 2009. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed 30 Nov 2022."},{"issue":"1","key":"929_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"issue":"1","key":"929_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12(1):107\u201328. https:\/\/doi.org\/10.1007\/s40120-022-00408-x.","journal-title":"Neurol Ther"},{"issue":"7","key":"929_CR47","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","volume":"45","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, Iacono S, Militello M, et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurol Sci. 2024;45(7):3481\u201394. https:\/\/doi.org\/10.1007\/s10072-024-07368-0.","journal-title":"Neurol Sci"},{"issue":"4","key":"929_CR48","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3988\/jcn.2023.0285","volume":"20","author":"JY Tan","year":"2024","unstructured":"Tan JY, Tan CY, Gengadharan PN, Shahrizaila N, Goh KJ. Clinical characteristics and outcomes of generalized myasthenia gravis in Malaysia: a single-center experience. J Clin Neurol. 2024;20(4):412\u201321. https:\/\/doi.org\/10.3988\/jcn.2023.0285.","journal-title":"J Clin Neurol"},{"issue":"1","key":"929_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7\u201316. https:\/\/doi.org\/10.25122\/jml-2020-0145.","journal-title":"J Med Life"},{"issue":"1","key":"929_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong D, Chong MK, Wu Y, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18(1):296. https:\/\/doi.org\/10.1186\/s12955-020-01549-z.","journal-title":"Health Qual Life Outcomes"},{"key":"929_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00845-4","author":"T Webb","year":"2025","unstructured":"Webb T, Kasahara-Kiritani M, Herr K, et al. Clinical status, treatment, and disease burden of generalised myasthenia gravis in the Asia-Pacific. Neurol Ther. 2025. https:\/\/doi.org\/10.1007\/s40120-025-00845-4.","journal-title":"Neurol Ther"},{"issue":"3","key":"929_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"key":"929_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1339167","volume":"15","author":"Y Ye","year":"2024","unstructured":"Ye Y, Murdock DJ, Chen C, Liedtke W, Knox CA. Epidemiology of myasthenia gravis in the United States. Front Neurol. 2024;15:1339167. https:\/\/doi.org\/10.3389\/fneur.2024.1339167.","journal-title":"Front Neurol"},{"issue":"10","key":"929_CR54","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jnnp-2023-333097","volume":"95","author":"J Vissing","year":"2024","unstructured":"Vissing J, Atula S, Savolainen M, et al. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study. J Neurol Neurosurg Psychiatry. 2024;95(10):919\u201326. https:\/\/doi.org\/10.1136\/jnnp-2023-333097.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"929_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241237495","volume":"17","author":"J van Enkhuizen","year":"2024","unstructured":"van Enkhuizen J, Binns J, Betts A, et al. A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England. Ther Adv Neurol Disord. 2024;17:17562864241237495. https:\/\/doi.org\/10.1177\/17562864241237495.","journal-title":"Ther Adv Neurol Disord"},{"key":"929_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100063.","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"929_CR57","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3988\/jcn.2016.12.3.340","volume":"12","author":"SY Park","year":"2016","unstructured":"Park SY, Lee JY, Lim NG, Hong YH. Incidence and prevalence of Myasthenia Gravis in Korea: a population-based study using the National Health Insurance Claims Database. J Clin Neurol. 2016;12(3):340\u20134. https:\/\/doi.org\/10.3988\/jcn.2016.12.3.340.","journal-title":"J Clin Neurol"},{"issue":"11","key":"929_CR58","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","volume":"19","author":"M Gattellari","year":"2012","unstructured":"Gattellari M, Goumas C, Worthington JM. A national epidemiological study of myasthenia gravis in Australia. Eur J Neurol. 2012;19(11):1413\u201320. https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03698.x.","journal-title":"Eur J Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00929-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:52Z","timestamp":1778681272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00929-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00929-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shiva Lauretta Birija, Joe Conyers, Hannah Connolly, and Gregor Gibson are employees of Adelphi Real World. DaeYoung Yu, Mami Kasahara-Kiritani, Bolam Lee, and I-Ching Tsai are employees of Johnson & Johnson group of companies and own Johnson & Johnson shares as part of employment remuneration. Yoon Ho Hong received research grants from the National Research Foundation of Korea, and received consultation fees from Biogen, Johnson & Johnson, Merck, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Using a checkbox, patients and caregivers provided informed consent to take part in the survey. Patient- and caregiver-reported questionnaires were completed independently from their neurologist and were returned in a sealed envelope, ensuring the responses were kept confidential from their neurologist. No identifiable protected health information was extracted during the course of the survey. Data were collected in such a way that patients and neurologists could not be identified directly, with data aggregated before being shared with the subscriber and for publication. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association (EphMRA) guidelines [\n                      \n                      ]. Exemption from ethics approval was sought and granted from Pearl IRB (study number AG9525). Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [\n                      \n                      ], and Health Information Technology for Economic and Clinical Health Act legislation [\n                      \n                      ] and the Helsinki Declaration of 1964 and subsequent revisions. All authors from Johnson & Johnson had permission to access the Adelphi Real World gMG DSP dataset through the subscription purchased by Johnson & Johnson. Other authors include employees of Adelphi Real World, the dataset owner. Data privacy regulations in South Korea meant that only retrospective DSP data could be collected. Prospective patient or caregiver self-reporting was therefore not conducted. No patient-reported data for Australia was presented due to no response. As a result of a lack of participation, there was no caregiver-reported data for Australia or Taiwan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}